CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
复制标题
DOI：
10.2214/ajr.183.6.01831619
复制
发表时间：
2004-12-01
影响因子：
5
通讯作者：
Podoloff, DA
中科院分区：
文献类型：
--
作者：
Choi, H;Charnsangavej, C;Podoloff, DA
客观的。我们将 CT 上肿瘤密度的变化与 FDG PET 上葡萄糖代谢或最大标准化摄取值 (SUVmax) 的变化相关联，并寻求制定 CT 成像标准，可用于客观评估接受甲磺酸伊马替尼治疗的转移性胃肠道间质瘤 (GIST) 患者的肿瘤反应。 材料和方法。使用实体瘤疗效评估标准 (RECIST) 小组制定的标准，我们选择了 173 个肿瘤（36 名患者）进行研究。客观确定肿瘤大小和密度，并根据 CT 图像主观评估总体肿瘤反应 (OTR)。治疗前后这些参数的变化与SUVmax的变化相关。结果。肿瘤密度均显着下降（平均 12.3 H [16.5%]；p
OBJECTIVE. We correlated changes in tumor density on CT with changes in glucose metabolism, or the maximum standardized uptake value (SUVmax), on FDG PET and sought to develop CT imaging criteria that can be used to objectively evaluate tumor response in patients with metastatic gastrointestinal stromal tumors (GISTs) who undergo treatment with imatinib mesylate.MATERIALS AND METHODS. Using the criteria established by the Response Evaluation Criteria in Solid Tumors (RECIST) group, we selected 173 tumors (in 36 patients) for study. Tumor size and density were determined objectively, and overall tumor response (OTR) was evaluated subjectively on CT images. The changes in these parameters before and after treatment were correlated with changes in SUVmax.RESULTS. Significant decreases were seen in both tumor density (mean, 12.3 H [16.5%]; p